EDP Sciences logo
Subscriber Authentication Point
rechercher
Menu
Accueil Tous les numéros Thérapie, 59 1 (2004) 5-12 Article's citations

Articles citing this article

The Citing articles tool gives a list of articles citing the current article.
The citing articles come from EDP Sciences database, as well as other publishers participating in CrossRef Cited-by Linking Program. You can set up your personal account to receive an email alert each time this article is cited by a new article (see the menu on the right-hand side of the abstract page).

Cited article:

Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone

Millicent G. A. Bennett, Ashley S. Meakin, Kimberley J. Botting-Lawford, Youguo Niu, Sage G. Ford, Michael P. Murphy, Michael D. Wiese, Dino A. Giussani and Janna L. Morrison
Pharmaceutics 17 (3) 285 (2025)
https://doi.org/10.3390/pharmaceutics17030285

Concomitant Administration of Psychotropic and Prostate Cancer Drugs: A Pharmacoepidemiologic Study Using Drug–Drug Interaction Databases

Daniel Ungureanu, Adina Popa, Adina Nemeș and Cătălina-Angela Crișan
Biomedicines 12 (9) 1971 (2024)
https://doi.org/10.3390/biomedicines12091971

Therapy of mental disorders in patients with hematological malignancies

D.E. Vybornykh, S.V. Ivanov, E.G. Gemdzhian, L.V. Esina and T.V. Gaponova
S.S. Korsakov Journal of Neurology and Psychiatry 124 (4) 127 (2024)
https://doi.org/10.17116/jnevro2024124041127

Activation syndrome in children and adolescents treated with selective serotonin reuptake inhibitors

Diana Marcela Pulzara Velasco and Laura Ospina-Pinillos
Revista Colombiana de Psiquiatría (English ed.) 53 (2) 184 (2024)
https://doi.org/10.1016/j.rcpeng.2022.03.004

Síndrome de Activación en Niños y Adolescentes Tratados con Inhibidores Selectivos de la Recaptación de Serotonina

Diana Marcela Pulzara Velasco and Laura Ospina Pinillos
Revista Colombiana de Psiquiatría 53 (2) 184 (2024)
https://doi.org/10.1016/j.rcp.2022.03.005

Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates

Myung-Eui Seo, Byung-Joo Min, Nayoon Heo, Kye Hwa Lee and Ju Han Kim
Frontiers in Pharmacology 14 (2023)
https://doi.org/10.3389/fphar.2023.1055991

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder

Cornelis F. Vos, Sophie E. ter Hark, Arnt F. A. Schellekens, Jan Spijker, Annemarie van der Meij, Anne J. Grotenhuis, Raluca Mihaescu, Wietske Kievit, Rogier Donders, Rob E. Aarnoutse, Marieke J. H. Coenen and Joost G. E. Janzing
JAMA Network Open 6 (5) e2312443 (2023)
https://doi.org/10.1001/jamanetworkopen.2023.12443

A.W. Jones, F. Musshoff, T. Krämer, A. E. Steuer, D. Gerostamoulos, O.H. Drummer, G. Drasch, M. Balikova, J. Beyer, H. Teixeira, M. Thevis, W. Schänzer, H. Druid and G. Skopp
1167 (2022)
https://doi.org/10.1002/9781119648628.ch52

Examination and characterisation of the effect of amitriptyline therapy for chronic neuropathic pain on neuropeptide and proteomic constituents of human cerebrospinal fluid

Jonathan Royds, Hilary Cassidy, Melissa J. Conroy, Margaret R. Dunne, Joanne Lysaght and Connail McCrory
Brain, Behavior, & Immunity - Health 10 100184 (2021)
https://doi.org/10.1016/j.bbih.2020.100184

An electrophysiological model of major depression: Relevance to clinical subtyping and pharmacological management

Ivo H. Cerda and Paul J. Fitzgerald
Psychiatry Research 303 114054 (2021)
https://doi.org/10.1016/j.psychres.2021.114054

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Yaser Pashaei
Journal of Clinical Neuroscience 88 163 (2021)
https://doi.org/10.1016/j.jocn.2021.03.010

Therapy Response Prediction in Major Depressive Disorder: Current and Novel Genomic Markers Influencing Pharmacokinetics and Pharmacodynamics

Alena Shalimova, Viktoria Babasieva, Vladimir N Chubarev, Vadim V Tarasov, Helgi B Schiöth and Jessica Mwinyi
Pharmacogenomics 22 (8) (2021)
https://doi.org/10.2217/pgs-2020-0157

Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population

Ivan Skadrić and Oliver Stojković
International Journal of Legal Medicine 134 (2) 433 (2020)
https://doi.org/10.1007/s00414-019-02234-7

ADME Pharmacogenetics: Future Outlook for Russia

Karin B Mirzaev, Denis S Fedorinov, Dmitry V Ivashchenko and Dmitry A Sychev
Pharmacogenomics 20 (11) 847 (2019)
https://doi.org/10.2217/pgs-2019-0013

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko and D. A. Sychev
Rational Pharmacotherapy in Cardiology 15 (3) 393 (2019)
https://doi.org/10.20996/1819-6446-2019-15-3-393-406

Effects of Digeda-4 Decoction on the CYP450 Activities in Rats Using a Cocktail Method by HPLC

Dong Zhang, Guo-dong Wu, Yan-dong Zhang, et al.
BioMed Research International 2018 1 (2018)
https://doi.org/10.1155/2018/1415082

Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

Davide Seripa, Madia Lozupone, Eleonora Stella, Giulia Paroni, Paola Bisceglia, Maddalena La Montagna, Grazia D’onofrio, Carolina Gravina, Maria Urbano, Maria Giovanna Priore, Angela Lamanna, Antonio Daniele, Antonello Bellomo, Giancarlo Logroscino, Antonio Greco and Francesco Panza
Expert Opinion on Drug Safety 16 (12) 1373 (2017)
https://doi.org/10.1080/14740338.2017.1389891

In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24

Pui Shen Lau, Kenny Voon Gah Leong, Chin Eng Ong, Amelia Nathania Hui Min Dong and Yan Pan
Biochemical Genetics 55 (1) 48 (2017)
https://doi.org/10.1007/s10528-016-9771-8

Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro

Qinghua Weng, Bingqing Liang, Yali Zhou, et al.
Pharmaceutical Biology 54 (11) 2475 (2016)
https://doi.org/10.3109/13880209.2016.1160250

Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients

Gino Giannaccini, Irene Masala, Lionella Palego, Laura Betti, Bruno Pacciardi, Laura Palagini, Federica Luchini, Simone Belli, Antonio Lucacchini and Mauro Mauri
Clinical Biochemistry 49 (15) 1152 (2016)
https://doi.org/10.1016/j.clinbiochem.2016.06.014

SSRI-Induced Activation Syndrome in Children and Adolescents—What Is Next?

Maya Amitai, Alon Chen, Abraham Weizman and Alan Apter
Current Treatment Options in Psychiatry 2 (1) 28 (2015)
https://doi.org/10.1007/s40501-015-0034-9

Acute fluoxetine modulates emotional processing in young adult volunteers

L. P. Capitão, S. E. Murphy, M. Browning, P. J. Cowen and C. J. Harmer
Psychological Medicine 45 (11) 2295 (2015)
https://doi.org/10.1017/S0033291715000240

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Ulrich M. Zanger and Matthias Schwab
Pharmacology & Therapeutics 138 (1) 103 (2013)
https://doi.org/10.1016/j.pharmthera.2012.12.007

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking

Margareta Ramsjö, Eleni Aklillu, Lilleba Bohman, et al.
European Journal of Clinical Pharmacology 66 (9) 871 (2010)
https://doi.org/10.1007/s00228-010-0835-0

Combining antidepressants: understanding drug interactions is the sine qua non

Ken Gillman
Advances in Psychiatric Treatment 16 (1) 76 (2010)
https://doi.org/10.1192/apt.16.1.76

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

P W Schenk, M van Vliet, R A A Mathot, T van Gelder, A G Vulto, M A C van Fessem, S Verploegh-Van Rij, J Lindemans, J A Bruijn and R H N van Schaik
The Pharmacogenomics Journal 10 (3) 219 (2010)
https://doi.org/10.1038/tpj.2009.50

Schizophrenie — Zukunftsperspektiven in Klinik und Forschung

Brigitta Bondy, I. Spellmann, R. Musil, et al.
Schizophrenie — Zukunftsperspektiven in Klinik und Forschung 219 (2010)
https://doi.org/10.1007/978-3-211-92215-6_17

Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression

Esther Berrocoso and Juan-Antonio Mico
The International Journal of Neuropsychopharmacology 12 (08) 1033 (2009)
https://doi.org/10.1017/S1461145709000236

Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

Louise Herbild, Mickael Bech and Dorte Gyrd-Hansen
Value in Health 12 (4) 560 (2009)
https://doi.org/10.1111/j.1524-4733.2008.00465.x

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Konstantinos A. Paschos, Stavroula Veletza and Ekaterini Chatzaki
CNS Drugs 23 (9) 755 (2009)
https://doi.org/10.2165/11310830-000000000-00000

Is norepinephrine an etiological factor in some types of cancer?

Paul J. Fitzgerald
International Journal of Cancer 124 (2) 257 (2009)
https://doi.org/10.1002/ijc.24063

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

Ulrich M. Zanger, Miia Turpeinen, Kathrin Klein and Matthias Schwab
Analytical and Bioanalytical Chemistry 392 (6) 1093 (2008)
https://doi.org/10.1007/s00216-008-2291-6

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients

P W Schenk, M A C van Fessem, S Verploegh-Van Rij, R A A Mathot, T van Gelder, A G Vulto, M van Vliet, J Lindemans, J A Bruijn and R H N van Schaik
Molecular Psychiatry 13 (6) 597 (2008)
https://doi.org/10.1038/sj.mp.4002057

Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms

Detlef Thieme, Burkhard Rolf, Hans Sachs and Dagmar Schmid
International Journal of Legal Medicine 122 (2) 149 (2008)
https://doi.org/10.1007/s00414-007-0184-4

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

Eric J. Peters, Susan L. Slager, Jeffrey B. Kraft, et al.
PLoS ONE 3 (4) e1872 (2008)
https://doi.org/10.1371/journal.pone.0001872

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

D Tomalik-Scharte, A Lazar, U Fuhr and J Kirchheiner
The Pharmacogenomics Journal 8 (1) 4 (2008)
https://doi.org/10.1038/sj.tpj.6500462

The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population

Jónrit Halling, Pál Weihe and Kim Brosen
British Journal of Clinical Pharmacology 65 (1) 134 (2008)
https://doi.org/10.1111/j.1365-2125.2007.02969.x

SSRI adverse events: How to monitor and manage

Tanya K. Murphy, Ana Segarra, Eric A. Storch and Wayne K. Goodman
International Review of Psychiatry 20 (2) 203 (2008)
https://doi.org/10.1080/09540260801889211

Patient preferences for pharmacogenetic screening in depression

Louise Herbild, Dorte Gyrd-Hansen and Mickael Bech
International Journal of Technology Assessment in Health Care 24 (1) 96 (2008)
https://doi.org/10.1017/S0266462307080129

Workshop outcomes report: Initiatives to establish a European Network of pharmacogenetics/genomics and progress

Anke Hilse Maitland-van der Zee, Katherine Aitchison and Julia Kirchheiner
European Journal of Pharmaceutical Sciences 31 (3-4) 151 (2007)
https://doi.org/10.1016/j.ejps.2007.03.009

Risk of adverse behavioral effects with pediatric use of antidepressants

Wayne K. Goodman, Tanya K. Murphy and Eric A. Storch
Psychopharmacology 191 (1) 87 (2007)
https://doi.org/10.1007/s00213-006-0642-6

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

Mugdha Thakur, Iris Grossman, Douglas C McCrory, et al.
Genetics in Medicine 9 (12) 826 (2007)
https://doi.org/10.1097/GIM.0b013e31815bf98f

Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine

Stefano Pallanti and Cláudio Sandner
International Journal of Psychiatry in Clinical Practice 11 (3) 233 (2007)
https://doi.org/10.1080/13651500701419685

Therapeutic Drug Monitoring of Antidepressants and Cytochrome P450 Genotyping in General Practice

Jenny E. Kootstra‐Ros, Marga J. M. Van Weelden, John W. J. Hinrichs, Peter A. G. M. De Smet and Jan van der Weide
The Journal of Clinical Pharmacology 46 (11) 1320 (2006)
https://doi.org/10.1177/0091270006293754

CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies

Anna Koski, Johanna Sistonen, Ilkka Ojanperä, et al.
Forensic Science International 158 (2-3) 177 (2006)
https://doi.org/10.1016/j.forsciint.2005.05.032

A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: A Case Report on Antidepressant Treatment

Maria Johnson, Courtney Markham-Abedi, Margaret T. Susce, et al.
CNS Spectrums 11 (10) 757 (2006)
https://doi.org/10.1017/S1092852900014887

Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions

M. D. Lee, E. Ayanoglu and L. Gong
Xenobiotica 36 (10-11) 1013 (2006)
https://doi.org/10.1080/00498250600861785

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19

Jose de Leon, Scott C. Armstrong and Kelly L. Cozza
Psychosomatics 47 (1) 75 (2006)
https://doi.org/10.1176/appi.psy.47.1.75

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

Henricus G. Ruhé, Jochanan Huyser, Jan A. Swinkels and Aart H. Schene
British Journal of Psychiatry 189 (4) 309 (2006)
https://doi.org/10.1192/bjp.bp.105.018325

Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies

Tiina Heikkilä, Tuula Lekander and Hannu Raunio
European Journal of Clinical Pharmacology 62 (8) 661 (2006)
https://doi.org/10.1007/s00228-006-0149-4

Re: no evidence of increased adverse drug reactions in cytochrome P450CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

P. K. Gillman
Human Psychopharmacology: Clinical and Experimental 20 (1) 61 (2005)
https://doi.org/10.1002/hup.659